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Abstract
Background—We used data from 4 years of pediatric severe acute respiratory illness (SARI) 
sentinel surveillance in Blantyre, Malawi, to identify factors associated with clinical severity and 
coviral clustering.
Methods—From January 2011 to December 2014, 2363 children aged 3 months to 14 years 
presenting to the hospital with SARI were enrolled. Nasopharyngeal aspirates were tested for 
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influenza virus and other respiratory viruses. We assessed risk factors for clinical severity and 
conducted clustering analysis to identify viral clusters in children with viral codetection.
Results—Hospital-attended influenza virus–positive SARI incidence was 2.0 cases per 10 000 
children annually; it was highest among children aged <1 year (6.3 cases per 10 000), and human 
immunodeficiency virus (HIV)–infected children aged 5–9 years (6.0 cases per 10 000). A total of 
605 SARI cases (26.8%) had warning signs, which were positively associated with HIV infection 
(adjusted risk ratio [aRR], 2.4; 95% confidence interval [CI], 1.4–3.9), respiratory syncytial virus 
infection (aRR, 1.9; 95% CI, 1.3–3.0) and rainy season (aRR, 2.4; 95% CI, 1.6–3.8). We identified 
6 coviral clusters; 1 cluster was associated with SARI with warning signs.
Conclusions—Influenza vaccination may benefit young children and HIV-infected children in 
this setting. Viral clustering may be associated with SARI severity; its assessment should be 
included in routine SARI surveillance.
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children; SARI; Africa; viral coinfection; influenza
It is estimated that, worldwide, the case-fatality rate of severe pneumonia in children aged 
<5 years is 8.9%, which, in 2011, amounted to 1.26 million deaths [1]. Much of this burden 
falls on sub-Saharan Africa, where severe acute respiratory infection (SARI), including 
pneumonia, is a leading cause of childhood hospital attendance and death [2]. Although 
laboratory diagnostic facilities are rarely available in such settings, sentinel surveillance 
using multiplex molecular diagnostic assays has recently provided considerable insight into 
the true burden of disease and the complexity of SARI etiology. Respiratory syncytial virus 
(RSV), parainfluenza viruses, rhinoviruses, influenza viruses, and adenovirus have been 
commonly detected in SARI surveillance across the African continent [3–8]. While there are 
a few viruses for which detection in respiratory disease cases is likely causal (eg, influenza 
virus and RSV) [9, 10], for other commonly identified viruses causality has been difficult to 
determine. Use of multiplex assays has led to an increasing realization that children with 
SARI commonly carry multiple viral pathogens that may potentially contribute to disease.
In the context of a low-income population with multiple drivers of immune compromise (eg, 
human immunodeficiency virus [HIV] infection, malnutrition, and malaria) [11], we 
conducted active surveillance at a large urban teaching hospital in Malawi to estimate the 
incidence of childhood SARI and explore the association of SARI clinical severity with HIV 
infection and clustering of respiratory viral coinfection. While previous studies have focused 
on children aged <5 years, we included children aged 3 months to 14 years in our analysis, 
to better capture the total burden and identify age groups particularly at risk.
METHODS
Study Site, Population, and Study Design
QECH is the only government inpatient facility for Blantyre (population, approximately 500 
000 children aged <15 years); it offers care free at the point of delivery. Overall, 13% of 
children aged <5 years in Malawi are moderately to severely underweight, and 4% are 
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experiencing wasting; 80.9% of children aged 12–23 months have received all Expanded 
Program on Immunization vaccinations [12]. There is no national routine influenza 
vaccination in Malawi. In 2010, a monovalent vaccine campaign targeting 2009 pandemic 
influenza A(H1N1) virus (A[H1N1]pdm09) achieved 74% coverage in pregnant women and 
7% of the overall population [13]. An estimated 2.5% of children aged <15 years are HIV 
infected [14]; the HIV prevalence in children aged <5 years on QECH nonsurgical pediatric 
wards is estimated at 6%. Blantyre has 2 distinct weather seasons, a rainy season (January–
April) and a cool dry season (May–August). Overall, 25.2% of Paediatric Accident and 
Emergency Unit (PAEU) patients have a malaria parasite–positive blood slide; malaria 
presentations to the PAEU peak from December to May.
Patients aged 3 months to 14 years presenting during surveillance hours (weekdays, from 
8:00 AM to 1:00 PM) from January 2011 through December 2014 were screened. 
Consecutive patients fulfilling the SARI case definition were recruited (maximum, 5 per 
day). Demographic and clinical data were captured through an electronic data collection 
system [15]. Nasopharyngeal aspirates (NPAs) were obtained and tested for influenza 
viruses; from 2011 to 2013, NPAs were also tested by multiplex assay for respiratory 
pathogens. Thick blood films for detection of malaria parasites were performed for all 
children.
SARI was defined as (1) an acute illness with symptom onset <7 days and (2) a reported or 
recorded fever of ≥38°C (or hypothermia in children <6 months). Additional criteria for 
SARI varied by age. In children aged <6 months, additional criteria were (3) cough or apnea 
or (4) any respiratory symptom requiring hospitalization. In children aged 6–59 months, an 
additional criterion was (3) clinician-diagnosed lower respiratory infection. In children aged 
6–14 years, additional criteria were (3) cough or sore throat and (4) shortness of breath or 
difficulty breathing. SARI with warning signs was considered clinically more severe and 
defined as the occurrence of one of the following: admission to the hospital, chest recession, 
or blood oxygen saturation of ≤90%. In this resource-limited setting, some patients with 
severe illness requiring admission were sent home. Thus, hospital attendance (not 
admission) was required for study enrollment.
Laboratory Procedures
NPAs were stored at −80°C in Universal Transport Medium (Copan, Brescia, Italy) [16] and 
tested in batches for influenza viruses by real-time reverse transcription–polymerase chain 
reaction (RT-PCR). Total nucleic acids were extracted from 300-μL aliquots of each 
specimen with the Qiagen BioRobot Universal System, using the QIAamp One-For-All 
nucleic acid kit (Qiagen, Manchester, United Kingdom). The quantity of nucleic acid used 
per reaction was 5 μL for the Centers for Disease Control and Prevention (CDC) Human 
Influenza real-time RT-PCR diagnostic panel (CDC Influenza Division), which detects 
influenza A and B viruses and influenza A subtypes H1, H3, 2009H1, and H5N1, and 10 μL 
for the FTD respiratory pathogens 33 kit (Fast-track Diagnostics, Luxembourg). Details on 
sample processing with by FTD real-time RT-PCR are provided in Appendix 1. HIV 
serostatus was assessed by the rapid test (Alere Determine HIV-1/2 and Trinity Biotech Uni-
Gold HIV) according to World Health Organization guidelines [17]. PCR for detection of 
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HIV RNA was performed in children aged 3–11 months who had a positive HIV rapid test. 
HIV infection was defined on the basis of positive results of an HIV rapid test (in the 
absence of an HIV-negative PCR); data were not collected on HIV exposure.
Ethics Approval
Ethics approval for this study was obtained from the Liverpool School of Tropical Medicine 
Research Ethics Committee (approval RETH000790), the University of Malawi College of 
Medicine Research Ethics Committee (COMREC; approval 958), and the CDC through 
reliance on the COMREC. Informed consent was obtained from guardians of all study 
participants.
Data Analysis
Numerators for minimum SARI incidence estimates were generated by summing the number 
of cases resident in Blantyre within strata of age category and HIV status. Numerators were 
adjusted by multiplying by the reciprocal of the daily proportion of recruited cases among 
all SARI cases attending the PAEU. Denominators for HIV and age strata were derived by 
applying age-specific HIV prevalence estimates to census figures for Blantyre District’s 
population aged 0–14 years [18]. The former were obtained by apportioning the total HIV 
prevalence among Malawian children aged <15 years [14] according to the age distribution 
of pediatric HIV infections in Mozambique, which borders Malawi and has a similarly 
severe HIV epidemic [19, 20]. Estimates of age-specific HIV prevalence were unavailable 
for Malawi for the study period. The incidence was obtained by dividing numerators by 
denominators and multiplying by 10 000; HIV-associated incidence rate ratios (IRRs) were 
calculated by dividing the incidence in HIV-infected strata by the incidence in HIV-
uninfected strata; 95% confidence intervals (CIs) of incidence and HIV-associated IRRs 
were generated with 1000 bootstrap samples.
Data analysis was performed using SAS 9.3 (SAS Institute, Cary, North Carolina). Temporal 
trends in weekly sample counts for SARI cases were assessed by plotting 5-week moving 
averages of sample counts by recruitment week. We developed 2 logistic regression models 
with a binary outcome factor for the child’s clinical status. The first outcome represented 
SARI with warning signs (ie, clinical markers of very severe illness) versus SARI without 
warning signs. The second outcome represented influenza virus–positive SARI versus 
influenza virus–negative SARI. Autoregressive correlation of residuals was removed by 
introducing a patient-level kernel weighted moving average of the prior probability of case 
status. Parsimonious models were developed by stepwise logistic regression, retaining age, 
sex a priori, and explanatory factors with a 2-sided P value of <.05. Adjusted relative risk 
ratios for factors associated with the outcomes were derived from these models.
Detection of multiple viruses in SARI is common, with many possible combinations of viral 
carriage. Conventional statistical techniques (eg, regression models, covariance matrices, 
and temporal plots) have limited capacity to quantify, characterize or identify factors 
associated with viral carriage groupings. To assess multiple virus carriage clusters in our 
setting, we performed nearest-neighbor discrete hierarchical cluster analysis in patients with 
viral codetection, using the Gower distance [21]. Distance was based on similarity of viral 
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pathogens detected in the nasopharynx of patients with SARI; each patient was a member of 
only 1 cluster. We defined clusters as those that increased the R2 value by ≥0.05 (using the 
Ward method); to improve precision, 10% of observations with the lowest densities were 
discarded. Using univariate logistic regression, we identified factors associated with cluster 
membership.
RESULTS
SARI Population
From 1 January 2011 to 31 December 2014, 2363 SARI cases (median age, 15 months; 
interquartile range [IQR], 8–27 months) were recruited. In total, 605 of 2260 SARI cases 
(26.8%) had clinical warning signs (Table 1; the Consolidated Standards of Reporting Trials 
diagram is available in Appendix 2). Warning signs were determined as follows: 489 of 605 
(80.8%) were hospitalized (median duration of stay, 2 days [IQR, 1–3 days]), 37 of 605 
(6.1%) had a blood oxygen saturation level of <90%, 75 of 605 (12.4%) had chest recession, 
and 4 of 605 (<1%) had both of these clinical features. In cases aged 3 to <12 months, 17 of 
247 (6.9%) had a positive HIV test result, compared with 29 of 563 (5.2%) aged 12 to <36 
months, 45 of 1050 (4.3%) aged 36–59 months, 19 of 241 (7.9%) aged 5–9 years, and 18 of 
103 (17.5%) aged 10–14 years. Eight of 17 HIV infections in cases aged 3 to <12 months 
(47.1%) were confirmed by PCR.
Viruses Detected in Association With SARI
We detected influenza viruses in 266 of 2363 SARI cases (11.3%). When tested for the 
extended panel of pathogens, influenza A and B viruses (any type) were detected in 201 of 
1835 cases (10.9%), rhinoviruses in 358 of 1835 (19.5%), RSV in 220 of 1835 (11.9%), and 
adenovirus in 162 of 1835 (8.8%). In 542 of 1835 SARI cases (30%), no viral pathogen was 
detected (Table 2).
Seasonality of Influenza Virus and RSV
Plots of weekly influenza virus–positive SARI cases suggest both unimodal and bimodal (2 
peaks per year) seasonality. Weekly influenza virus–positive SARI cases increased during 
the rainy season (January–April) in all 4 years of surveillance. A second peak of influenza 
virus–positive SARI cases, occurring during September–October, was confined to 2013 and 
2014 (Figure 1). In multivariable analysis, influenza virus detection during SARI increased 
in the rainy season (adjusted risk ratio [aRR], 3.3; 95% CI, 1.9–5.4) and the cool dry months 
(May–August; aRR, 2.1; 95% CI, 1.2–3.6), compared with September–December (Table 3). 
Influenza virus detection in SARI was significantly higher in the rainy season as compared 
to the cool dry season (aRR, 1.6, 95% CI, 1.0–2.5). The predominance of influenza virus 
types varied within and between years. A(H1N1)pdm09 was most prevalent in the first half 
of 2011 and 2013; influenza A(H3N2) and influenza B viruses were most prevalent in 2012, 
in the latter half of 2013, and in 2014. In contrast, RSV infection displayed regular 
seasonality, with peaks in the first half of the rainy season (January–March; Figure 1).
Peterson et al. Page 5
J Infect Dis. Author manuscript; available in PMC 2017 March 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Incidence Estimates for SARI and Respiratory Virus–Associated SARI
SARI incidence was 17.5 cases per 10 000 children annually, with the highest incidence in 
children aged 3–11 months (89.5; 95% CI, 85.8–93.0). Influenza virus–positive SARI 
incidence was 2.0 cases per 10 000 children annually and was highest in children aged 3–11 
months (6.3; 95% CI, 5.3–7.6). The incidence of RSV-positive SARI cases per 10 000 
children annually was 4.6 (95% CI, .1–15.8) and was highest in children aged 3–11 months 
(17.3; 95% CI, 13.7–18.6; Table 4).
Risk Factors for SARI With Warning Signs and Virus-Associated SARI
We found that 390 of 1505 patients with SARI (25.9%) had warning signs, among whom 
309 of 390 (79.2%) were hospitalized. In multivariable analysis, RSV was the only pathogen 
associated with SARI with warning signs (aRR, 1.9; 95% CI, 1.3–3.0). Nevertheless, 52 of 
249 influenza virus–positive SARI cases (20.9%) required hospitalization. A positive HIV 
test result was associated with a 2-fold increased risk of SARI with warning signs (aRR, 2.4; 
95% CI, 1.4–3.9; Table 5), as well as an increased incidence of SARI, SARI with warning 
signs, and influenza virus–positive SARI (Table 4). HIV-associated IRRs rose with 
increasing age. The HIV-associated IRRs for SARI with warning signs was 2.6 in children 
aged 3–11 months as compared to 37.7 in children aged 10–14 years. In children aged >5 
years, the incidence of hospital-attended influenza virus–positive SARI was at least 8-fold 
higher in HIV-infected children as compared to HIV-uninfected children. There was no 
difference in the incidence of RSV-positive SARI between HIV-infected and HIV-uninfected 
children.
In multivariable analysis controlling for etiology, patients with SARI recruited during the 
rainy season (January–April) were more than twice as likely to have warning signs, 
compared with patients enrolled during September–December (aRR, 2.4; 95% CI, 1.6–3.8; 
Table 5). Peaks in RSV and influenza virus activity corresponded to peaks in the occurrence 
of SARI with warning signs (Figure 1). Detection of RSV in cases of SARI warning signs 
was much higher during the rainy season (39.8%) as compared to other times of year (5.9%).
The aRR for a positive results of an influenza virus test in patients with SARI increased with 
older age and rainy season of recruitment (Table 3). After adjustment for age, sex, and HIV 
status, rainy season recruitment was significantly associated with SARI with warning signs 
in influenza virus–positive patients with SARI (aRR, 3.42; 95% CI, 1.37–8.53; analysis not 
shown). In adjusted analysis, A(H1N1)pdm09 was associated with double the risk of SARI 
with warning signs, compared with other influenza virus subtypes (aRR, 2.10; 95% CI, .98–
4.53; analysis not shown).
Coviral Infection, Viral Clustering, and Clinical Severity in SARI
Detection of ≥2 viral pathogens by multiplex PCR occurred in 362 of 1835 SARI cases 
(19.7%). Viral codetection was highest in SARI cases positive for coronavirus 229 (70.6%) 
and enterovirus (79.7%). Viral codetection was least common in SARI cases testing positive 
for A(H1N1)pdm09 (27.3%), influenza A(H3N2) virus (29.0%), and RSV (29.5%) (Table 
2).
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Viral codetection per se was not associated with warning signs in SARI (Table 5). We used 
discrete hierarchical cluster analysis based on similarity of viral pathogens detected by 
multiplex PCR assay in SARI cases to explore whether particular groupings of viruses were 
associated with warning signs, host factors, or seasonal factors. We identified 6 clusters, 
which accounted for 48.3% of the total variation in viral pathogen test results in children 
with viral codetection. Cluster size ranged from 23 to 96 members; smaller clusters had 
fewer viral pathogens and lower within-cluster heterogeneity. Clusters were distinguishable 
by the type of viral pathogens detected. For example, 80% of influenza A(H3N2) viruses 
detected were found in cluster A; >65% of bocaviruses detected were found in cluster E 
(Appendix 3).
Cluster membership was significantly associated with clinical and temporal factors (Figure 
2). Among children with viral codetection, membership in cluster D (characterized by 
A(H1N1)pdm09, RSV, and coronaviruses 43 and 63) was associated with nearly double the 
risk of SARI with warning signs (OR, 1.9; 95% CI, 1.2–3.5; analysis not shown), compared 
with other clusters. In cluster D, 47 of 70 members (67%) had RSV or A(H1N1)pdm09 
infection (Appendix 3); 11.4% of members had RSV and A(H1N1)pdm09 coinfection, 
accounting for all such coinfections in patients with SARI. Rainy season recruitment was 
significantly associated with cluster D, while dry season recruitment was significantly 
associated with cluster B (characterized by parainfluenza viruses 2 and 3). Clusters were 
also significantly associated with temporal peaks in viral pathogen activity. For example, 
65% of cluster A members were recruited during a peak in influenza A(H3N2) virus activity 
that occurred from September to December in 2013 (Figures 1 and 2), compared with 13.3% 
of other children with viral codetection. Cluster membership was not associated with host 
factors (age, sex, HIV status, and underweight).
DISCUSSION
Hospital-attended SARI was common in this urban sub-Saharan African setting, particularly 
in infants aged 3–11 months, in whom the incidence was 91.7 cases per 10 000 children 
annually. Similar to studies from other settings, influenza viruses and RSV were important 
SARI-associated pathogens [5–8, 22, 23], with prevalence rates of 11% and 12%, 
respectively. As elsewhere, HIV infection increased the risk of SARI and the presence of 
warning signs in SARI cases [24–26]. Among older children, HIV infection greatly 
increased the risk of influenza virus–positive SARI, consistent with data from South Africa 
[25].
Viral coinfection occurred in almost 20% of SARI cases, highlighting its potential impact in 
the development or clinical worsening of SARI [27]. Although viral codetection per se was 
not associated with clinical severity or season, we found 1 viral cluster, characterized by a 
high proportion of RSV and A(H1N1)pdm09 infection, which was significantly associated 
with clinical warning signs and rainy season recruitment. Cluster members coinfected with 
RSV and A(H1N1)pdm09 had a higher rate of warning signs, but the number of coinfected 
individuals (within the cluster and the entire sample) was too small to formally test for 
interaction. It is unclear therefore whether clinical severity in this cluster resulted from 
biological interaction of pathogens, additive risks from each pathogen, or other underlying 
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factors. Clusters clearly mapped to peaks and troughs in individual pathogen activity. We 
suggest that this viral clustering, which was associated temporal dynamics of pathogen 
activity, may have arisen from complex virus-virus and host-virus pathogen interactions.
Clinical severity in SARI demonstrated seasonal peaks, coinciding with rainy season peaks 
in RSV activity. RSV was detected in 40% of SARI cases with warning signs recruited 
during the rainy season, compared with 6% recruited at other times of the year. Thus, RSV 
may drive rainy season increases in clinical severity in pediatric SARI in our setting, 
consistent with studies elsewhere in sub-Saharan Africa [28, 29]. Nevertheless, the rainy 
season remained independently associated with an increased risk of warning signs in SARI 
in multivariable analysis controlling for RSV, HIV, and other viral pathogens. Therefore, the 
observed rainy season excess of clinical severity in SARI is in part attributable to 
unmeasured factors. We speculate that these factors include other intervening illnesses and 
seasonal malnutrition (in Malawi, the rainy season coincides with the so-called lean season 
after harvest [30]). However, we cannot exclude seasonal differences in healthcare 
utilization.
We acknowledge that our study has limitations. We did not recruit children aged <3 months, 
in whom the frequency of SARI-related deaths is known to be elevated [31]. We were unable 
to determine the role of bacterial pathogens in SARI, as we lacked laboratory data and 
systematic radiological data to identify probable infection in the context of a very high 
prevalence of bacterial carriage. Our estimates of SARI incidence by HIV strata were based 
on Mozambican pediatric HIV prevalence rates because we lacked data from Malawi. 
Nevertheless, Malawi and Mozambique have similar rates of antenatal HIV prevalence [12, 
32, 33] and similarly high rates of HIV-infected pregnant women accessing antiretroviral 
treatment [34]. We did not assess the impact of HIV exposure on SARI risk in HIV-
uninfected children. HIV exposure was associated with higher SARI incidence and greater 
SARI severity in HIV-uninfected South African children [35].
In conclusion, SARI is common in this setting of high HIV prevalence, where influenza 
viruses, rhinoviruses, and RSV were the most prevalent viruses detected. HIV greatly 
increased the risk of influenza virus–associated SARI in children, and therefore yearly 
influenza vaccination should be considered in routine pediatric HIV clinical care. Influenza 
vaccination in HIV-infected children is safe, but it has low efficacy (<20%) and may only be 
immunogenic in older children and adolescents with virological suppression [36–38]. Viral 
coinfection was common, with 1 coviral cluster associated with clinical severity in SARI 
cases. In this context, there is considerable potential for the use of multiplex respiratory 
virus assays in tandem with cluster analysis to reveal multiple-pathogen–associated 
outbreaks and disease burden. This approach may expose the potential for synergistic effects 
of vaccine strategies that disrupt viral clusters. Vaccine probe studies to assess the impact of 
viral coinfection on clinical severity could clarify complex pathogen and host 
interrelationships and reveal the true burden of disease.
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APPENDIX 1
Description of implementation of FTF multiplex assay FTD rRT-PCR assay was used in 
combination with the AgPath one-step qRT-PCR reagents according to the manufacturer’s 
instructions (Applied Biosystems, Carlsad, California, USA). Viral pathogens included in 
the FTD kit were: influenza A, B and C viruses, coronaviruses OC43, NL63, HKU1 and 
229E, parainfluenza viruses 1–4; RSVA and B; enteroviruses; human metapneumovirus; 
rhinoviruses; adenovirus; bocavirus; and parechoviruses. Samples with a Ct-value <40 were 
recorded as positive.
APPENDIX 2
Consolidated Standards of Reporting Trials diagram of data analyses. Abbreviations: FTD, 
FTD respiratory pathogens 33 kit; HIV, human immunodeficiency virus; SARI, severe acute 
respiratory infection.
APPENDIX 3
Viral pathogens detected in 6 clusters identified by discrete hierarchical cluster analysis of 
pediatric severe acute respiratory infection (SARI) cases with viral codetection. 
Abbreviations: AV, adenovirus; BocaV, bocavirus; Cor43, coronavirus 43; Cor63, 
coronavirus 63; Cor229, coronavirus 229; FluC, influenza C virus; H1N1, 2009 pandemic 
influenza A(H1N1) virus; H3, influenza A(H2N3) virus; HMPV, human metapneumovirus; 
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Para 3, parainfluenza virus 1; Para 2, parainfluenza virus 2; PV, parechovirus; Rhino, 
Rhinovirus; RSV, respiratory syncytial virus.
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Figure 1. 
Seasonal plots of severe acute respiratory infection (SARI) with warning signs, influenza 
virus infection, and respiratory syncytial virus (RSV) infection in pediatric SARI cases, 
Blantyre, Malawi, 2011–2014. A, The red line denotes influenza virus–positive SARI, the 
dotted black line denotes SARI with warning signs, and the dotted gray line denotes SARI 
cases tested. B, The red bars denote 2009 pandemic influenza A(H1N1) virus, the green bars 
denotes influenza A(H2N3) virus, the yellow bars denote influenza B virus, and the purple 
bars denote other influenza virus types. C, The red line denotes RSV-positive SARI, the 
dotted black line denotes SARI with warning signs, and the dotted gray line denotes SARI 
cases tested.
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Figure 2. 
Dendrogram of coviral clusters. Six coviral clusters (A–F) were identified in 362 pediatric 
SARI cases, in whom >2 viral pathogens were detected in the nasopharynx. Each severe 
acute respiratory infection (SARI) case is a member of only one cluster; clusters 
membership is based on similarity of viral pathogens detected. As shown here, 
characteristics such as SARI severity, number of viruses detected per child, and particular 
season and year of recruitment are more common in some clusters than others. Green bars 
denote SARI without warning signs, red bars denote SARI with warning signs, bluish-gray 
bars denote detection of <3 viruses detected, orange bars denote detection of ≥3 viruses, 
lavender bars denote recruitment in the rainy season, yellow bars denote recruited outside of 
the rainy season, gray bars denote recruitment in 2011, blue bars denote recruitment in 2012, 
pink bars denote recruitment in 2013, and light green bars denote recruitment in 2014.
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Table 4
Incidence of Severe Acute Respiratory Illness (SARI) in Children Residing in Blantyre City, Malawi, by SARI 
Type, Age, and Human Immunodeficiency Virus (HIV) Status
SARI Group, Age Group HIV Uninfected Incidence per 10 000 (95% CI)
HIV Infected
Incidence per 10 000 (95% CI) IRR (95% CI)
Overall
 <1 y 89.5 (85.8–93.0) 155.3 (127.3–191.1) 1.7 (1.41–2.14)
 12–59 mo 35.8 (34.9–36.9) 73.3 (64.7–87.8) 2.0 (1.82–2.44)
 5–9 y 1.3 (1.0–1.6) 16.0 (9.9–24.2) 12.6 (7.69–19.21)
 10–14 y 0.8 (.7–1.0) 7.9 (5.5–12.7) 9.6 (6.52–17.10)
SARI with warning signs
 <1 y 16.5 (15.2–18.0) 43.1 (29.4–60.7) 2.6 (1.66–3.61)
 12–59 mo 7.2 (6.7–7.5) 30.1 (24.4–40.3) 4.2 (3.34–5.91)
 5–9 y 0.4 (.3–.5) 9.0 (6.0–15.6) 24.3 (13.51–51.03)
 10–14 y 0.1 (.1–.2) 3.3 (1.4–6.7) 37.7 (11.10–93.21)
Hospitalized SARI
 <1 y 12.3 (11.1–13.8) 25.9 (14.9–37.2) 2.1 (1.1–3.0)
 12–59 mo 5.4 (4.9–5.7) 21.9 (16.7–30.1) 4.1 (3.0–5.9)
 5–9 y 0.3 (.2–.4) 6.0 (2.9–11.0) 21.3 (9.2–48.7)
 10–14 y 0.1 (.0–.2) 3.3 (.7–5.6) 37.7 (11.1–109.9)
Influenza virus–positive SARI
 <1 y 6.3 (5.3–7.6) 6.5 (2.2–15.4) 1.0 (.40–2.51)
 12–59 mo 4.9 (4.6–5.2) 3.7 (1.5–8.5) 0.7 (.30–1.79)
 5–9 y 0.3 (.2–.4) 6.0 (2.0–11.8) 21.3 (6.76–42.07)
 10–14 y 0.2 (.2–.4) 0.9 (.2–2.1) 8.1 (2.79–19.74)
RSV-positive SARI
 <1 y 17.3 (16.2–19.3) 17.3 (8.4–29.2) 0.9 (.5–1.7)
 12–59 mo 3.2 (2.9–3.3) 4.9 (2.0–9.3) 1.5 (.6–3.0)
 5–9 y 0.1 (.1–.2) 0.0 (.0–.0) 0.0 (.0–.0)
 10–14 y 0.0 (.0–.0) 1.8 (.9–4.6)
. . .
a
Analyses based on 131 HIV-infected SARI cases, 53 HIV-infected cases of SARI with warning signs, 48 HIV-infected hospitalized SARI cases, 11 
HIV-infected influenza virus–positive SARI cases, and 13 HIV-infected RSV-positive SARI cases.
Abbreviations: CI, confidence interval; IRR, HIV-associated incidence rate ratio; RSV, respiratory syncytial virus.
a
Inestimable.
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